Phase II study of Docetaxel, Carboplatin, and Trastuzumab (THC) as first-line treatment in patients with HER-2 amplified advanced breast cancer. Changes in circulating tumor cells (CTC), total plasma DNA and circulating HER-2 ECD

L.Dirix; Benoy; A.Prové; H.Elst; J.Vandebroeck; H.Wuyts; M.Philips; I.Deleu; P.Van Dam; P.Vermeulen

首页> 外文期刊>European Journal of Cancer Supplements >Phase II study of Docetaxel, Carboplatin, and Trastuzumab (THC) as first-line treatment in patients with HER-2 amplified advanced breast cancer. Changes in circulating tumor cells (CTC), total plasma DNA and circulating HER-2 ECD

【24h】

Phase II study of Docetaxel, Carboplatin, and Trastuzumab (THC) as first-line treatment in patients with HER-2 amplified advanced breast cancer. Changes in circulating tumor cells (CTC), total plasma DNA and circulating HER-2 ECD

机译：多西他赛，卡铂和曲妥珠单抗（THC）作为HER-2扩增晚期乳腺癌患者的一线治疗的II期研究。循环肿瘤细胞（CTC），血浆总DNA和循环HER-2 ECD的变化

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2006年第2期|共1页
作者
L.Dirix; Benoy; A.Prové; H.Elst; J.Vandebroeck; H.Wuyts; M.Philips; I.Deleu; P.Van Dam; P.Vermeulen;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. [J] . Valero V, Forbes J, Pegram MD, Journal of Clinical Oncology . 2011,第2期

机译：多中心紫杉醇和曲妥珠单抗与多西紫杉醇，卡铂和曲妥珠单抗作为HER2基因扩增转移性乳腺癌患者的一线化疗方案的比较（BCIRG 007研究）：两种高度活跃的治疗方案。
2. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. [J] . Gasparini G, Gion M, Mariani L, Breast cancer research and treatment. . 2007,第3期

机译：每周单独紫杉醇与曲妥珠单抗加每周紫杉醇作为Her-2阳性晚期乳腺癌患者的一线治疗的随机II期试验。
3. OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC) [J] . N.Yamamoto, Y.Ichinose, Y.Nishiwaki, European Journal of Cancer Supplements . 2009,第4期

机译：基于IPASS的日本患者（pts）子集中的循环游离DNA（cfDNA）进行的OP78 EGFR突变（IRESSA泛亚研究），这是一线吉非替尼（G）与卡铂/紫杉醇（C / P）的III期研究临床选择的晚期非小细胞肺癌（NSCLC）患者
4. PHASE II OPEN-LABEL STUDY OF SINGLE-AGENT HYDROXYUREA FOR TREATMENT OF ADVANCED CUTANEOUS MAST CELL TUMORS IN DOGS [C] . Ken Rassnick, Renee Al-Sarraf, Dennis Bailey, Annual Conference of the Veterinary Cancer Society . 2009

机译：单药羟基脲的第II期开放标签研究，用于治疗犬晚皮腰肿瘤瘤
5. Phase II study of bevacizumab cisplatin and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016 [O] . Satoshi Ikeda, Terufumi Kato, Takashi Ogura, 2018

机译：贝伐单抗顺铂和多西他赛加维持贝伐单抗作为晚期非鳞状非小细胞肺癌患者的一线治疗并结合循环内皮细胞的探索性分析的II期研究：胸腔肿瘤研究小组（TORG）1016
6. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. [O] . Gasparini G, Gion M, Mariani L, 2006

机译：每周单独紫杉醇与曲妥珠单抗加每周紫杉醇作为Her-2阳性晚期乳腺癌患者的一线治疗的随机II期试验。
7. Biological Monitoring of HER-2 Positive Patients Using Serum HER-2 and Circulating Tumor Cells [R] . Dias, C. C. , Harris, L. N. 2004

机译：血清HER-2和循环肿瘤细胞对HER-2阳性患者的生物学监测

Phase II study of Docetaxel, Carboplatin, and Trastuzumab (THC) as first-line treatment in patients with HER-2 amplified advanced breast cancer. Changes in circulating tumor cells (CTC), total plasma DNA and circulating HER-2 ECD

著录项

引文网络

相似文献

相关主题

期刊订阅